NasdaqGS - Delayed Quote • USD
FibroGen, Inc. (FGEN)
At close: April 24 at 4:00 PM EDT
After hours: April 24 at 6:48 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 2 | 2 | 3 | 3 |
Avg. Estimate | -0.42 | -0.39 | -1.33 | -0.44 |
Low Estimate | -0.53 | -0.48 | -1.8 | -1.19 |
High Estimate | -0.31 | -0.3 | -1.03 | 0.69 |
Year Ago EPS | -0.81 | -0.9 | -2.92 | -1.33 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 2 | 2 | 3 | 3 |
Avg. Estimate | 36.67M | 37.67M | 155.41M | 169.44M |
Low Estimate | 31.89M | 32.91M | 136.09M | 147.03M |
High Estimate | 41.44M | 42.44M | 172M | 196M |
Year Ago Sales | 31.84M | -- | 147.75M | 155.41M |
Sales Growth (year/est) | 15.20% | -- | 5.20% | 9.00% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.75 | -0.7 | -0.68 | -0.42 |
EPS Actual | -0.81 | -0.9 | -0.65 | -0.57 |
Difference | -0.06 | -0.2 | 0.03 | -0.15 |
Surprise % | -8.00% | -28.60% | 4.40% | -35.70% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.42 | -0.39 | -1.33 | -0.44 |
7 Days Ago | -0.41 | -0.4 | -1.29 | -0.43 |
30 Days Ago | -0.41 | -0.4 | -1.29 | -0.43 |
60 Days Ago | -0.4 | -0.37 | -1.28 | -0.22 |
90 Days Ago | -0.43 | -0.4 | -1.36 | -0.41 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | 1 | -- | -- |
Up Last 30 Days | -- | 1 | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | 1 | -- | 1 | 1 |
Growth Estimates
CURRENCY IN USD | FGEN | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 48.10% | -- | -- | 1.50% |
Next Qtr. | 56.70% | -- | -- | 11.40% |
Current Year | 54.50% | -- | -- | 5.20% |
Next Year | 66.90% | -- | -- | 13.40% |
Next 5 Years (per annum) | -- | -- | -- | 11.09% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Downgrade | B of A Securities: Neutral to Underperform | 8/8/2023 |
Maintains | Goldman Sachs: Sell to Sell | 6/27/2023 |
Downgrade | Raymond James: Outperform to Market Perform | 6/27/2023 |
Downgrade | B of A Securities: Buy to Neutral | 6/26/2023 |
Downgrade | Stifel: Buy to Hold | 6/26/2023 |
Downgrade | Raymond James: Outperform to Market Perform | 6/26/2023 |
Related Tickers
AKBA Akebia Therapeutics, Inc.
1.3700
0.00%
RARE Ultragenyx Pharmaceutical Inc.
44.28
-1.84%
XLO Xilio Therapeutics, Inc.
1.0600
+0.95%
ATRA Atara Biotherapeutics, Inc.
0.7147
-0.54%
ANVS Annovis Bio, Inc.
12.74
+7.24%
RLYB Rallybio Corporation
1.5800
-9.20%
KPTI Karyopharm Therapeutics Inc.
1.0900
0.00%
GTHX G1 Therapeutics, Inc.
3.9900
-4.77%
GOSS Gossamer Bio, Inc.
0.7083
-3.97%
CHRS Coherus BioSciences, Inc.
2.0200
-7.34%